Business Context and Reporting Period
Company: D. Boral ARC Acquisition I Corp. (BCAR), a British Virgin Islands corporation and emerging growth company.
Reporting Date: January 11, 2026.
Event: BCAR entered into a definitive Agreement and Plan of Merger to combine with Exascale Labs Inc. ("Exascale"), a Delaware corporation. The transaction involves a two-step process: (1) BCAR reincorporating in Delaware via a merger with its subsidiary PubCo, and (2) PubCo acquiring Exascale through a merger with Merger Sub.
Key Financial Metrics and Transaction Terms
Merger Consideration: The aggregate consideration for the acquisition is $500,000,000.
Payment Structure: Payable in 50,000,000 newly issued shares of PubCo common stock, valued at $10.00 per share.
Capitalization Details:
- Exascale Class B common stock converts to PubCo Class B shares (20 votes per share).
- Exascale Class A common stock converts to PubCo Class A shares (1 vote per share).
- Outstanding Simple Agreements for Future Equity (SAFEs) will convert to PubCo Class A shares based on liquidity event terms.
Financial Statements: The filing does not provide specific revenue, profit, cash flow, or debt metrics for BCAR or Exascale. It notes that Exascale must deliver Audited and Interim Financial Statements by January 31, 2026, as a condition to closing.
Material Changes and Transaction Structure
Corporate Structure Change: BCAR will reincorporate from the British Virgin Islands to Delaware. Post-closing, Exascale will become a wholly-owned subsidiary of the surviving entity, PubCo.
Board Composition: Immediately following the closing, PubCo's board will consist of five directors, all designated by Exascale.
Shareholder Support:
- Exascale's majority shareholder has entered a support agreement to vote in favor of the transaction.
- BCAR's Sponsor (MFH 1, LLC) has entered a support agreement to vote in favor of the transaction.
Guidance, Risks, and Conditions to Closing
Conditions to Closing:
- Approval by BCAR shareholders.
- Approval of the Nasdaq initial listing application.
- SEC approval of the proxy statement/prospectus.
- Accuracy of representations and warranties by both parties.
- No Material Adverse Effect on BCAR.
Termination Rights: The agreement may be terminated if the closing does not occur by the "Outside Date" of September 1, 2026, or if shareholder approval is not obtained.
Lock-Up Agreement: Exascale's majority shareholder is subject to a six-month lock-up period post-closing, restricting the sale or transfer of PubCo securities, subject to customary exceptions and a "Change of Control" release.
Risks and Forward-Looking Statements: The filing highlights risks including regulatory review outcomes, general economic conditions, adoption rates of AI technologies, and the possibility that the transaction may not be completed. Management commentary regarding future growth and market opportunity is included in the press release but is not guaranteed.
Investor Verification Checklist
- Verify the final valuation and share exchange ratio once the fully diluted Exascale capitalization is confirmed in the upcoming proxy statement.
- Review the Audited and Interim Financial Statements of Exascale expected by January 31, 2026, to assess financial health.
- Monitor the status of the Form S-4 registration statement and proxy statement/prospectus for detailed risk factors and transaction terms.
- Confirm the outcome of the BCAR shareholder vote required to approve the business combination.
- Check for any updates regarding the Nasdaq listing approval for the combined entity.